Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/80w01g59

IL-6 BLOCKADE WITH TOCILIZUMAB: EMERGING HORIZONS IN CONNECTIVE TISSUE DISEASE MANAGEMENT

[1*]Dr Balakrishnan Navaneethakrishnan,[2] Dr Mahabaleshwar Mamadapur, [3]Dr Sabarinath Mahadevan

[1*]Consultant Rheumatologist, Avinash hospitals, Chennai, Tamil Nadu, India. Email- nbkzzzz22@gmail.com ORCID ID: 0000-0003-1607-6563.
[2]Assistant Professor, Department of Clinical Immunology and Rheumatology, JSS Medical College, JSS Academy of Higher Research, Mysuru Email- mahabaleshwarm@jssuni.edu.in ORCID ID: 0000-0001-7421-2418.
[3]Assistant Professor, Institute of Rheumatology, Madras Medical College, Chennai, Tamil Nadu Email- msabari1987@gmail.com ORCID ID: 0000-0002-4868-1883.

[*]**Corresponding Author** - Dr Balakrishnan Navaneethakrishnan
***Email:** nbkzzzz22@gmail.com

ABSTRACT

Interleukin-6 (IL-6) is a key pleiotropic cytokine involved in immune regulation, inflammation, and fibrosis, playing a central role in the pathogenesis of several connective tissue diseases (CTDs). Tocilizumab, a humanized monoclonal antibody targeting both soluble and membrane-bound IL-6 receptors, has emerged as an important therapeutic agent across a spectrum of immune-mediated disorders. This narrative review summarizes the mechanism of action, pharmacokinetics, and clinical efficacy of tocilizumab in major connective tissue and related inflammatory diseases.

Tocilizumab inhibits IL-6–mediated classical and trans-signaling pathways, resulting in suppression of downstream JAK-STAT and MAPK signaling, reduction of acute-phase reactants, and modulation of adaptive immune responses. Pharmacokinetic properties are characterized by nonlinear, dose-dependent clearance and a terminal half-life of 8–14 days, with clinically relevant effects on cytochrome P450 metabolism.Clinical evidence supporting tocilizumab varies across disease entities. Robust efficacy has been demonstrated in giant cell arteritis and multicentric Castleman disease, where randomized controlled trials show sustained remission and significant glucocorticoid-sparing effects. In systemic sclerosis, particularly systemic sclerosis–associated interstitial lung disease, tocilizumab has shown consistent preservation of lung function, leading to regulatory approval in selected populations. Moderate evidence supports its use in adult-onset Still's disease and refractory Takayasu arteritis. In contrast, randomized trials in systemic lupus erythematosus, primary Sjögren's syndrome, and idiopathic inflammatory myopathies have yielded limited or negative results, restricting its use to experimental or highly selected refractory cases. Overall, tocilizumab represents a targeted, disease-modifying therapy with variable efficacy across connective tissue diseases. Optimal patient selection and further biomarker-driven trials are essential to refine its role in conditions with heterogeneous clinical responses.

INTRODUCTION

Interleukin-6 (IL-6) is a pleiotropic cytokine with a central role in immune regulation, inflammation, hematopoiesis, and tissue remodeling. Dysregulated IL-6 production contributes to the pathogenesis


of a wide range of immune-mediated and autoinflammatory diseases by promoting B-cell differentiation, autoantibody production, T-cell activation, and acute-phase responses [1,2]. IL-6 exerts its biological effects through two distinct mechanisms: classical signaling via membrane-bound IL-6 receptors and trans-signaling mediated by soluble IL-6 receptors, both of which activate intracellular JAK-STAT and MAPK pathways [1,3]. Persistent activation of these pathways results in chronic inflammation, fibrosis, and organ damage.

Tocilizumab is a humanized monoclonal IgG1 antibody that selectively inhibits IL-6 signaling by binding to both soluble and membrane-bound IL-6 receptors. By blocking IL-6–dependent signaling, tocilizumab effectively suppresses inflammatory cascades and normalizes acute-phase reactants, providing a strong mechanistic rationale for its use in IL-6–driven disorders [1,4]. Beyond its immunomodulatory effects, IL-6 inhibition also influences hepatic cytochrome P450 activity, highlighting the systemic biological impact of this cytokine and its therapeutic blockade [5].

Over the past decade, tocilizumab has emerged as an important targeted therapy across a spectrum of connective tissue and inflammatory diseases, with well-established efficacy in conditions such as giant cell arteritis and Castleman disease, and evolving evidence in systemic sclerosis, vasculitis, and other immune-mediated disorders. Understanding the mechanistic basis of IL-6 inhibition is essential for optimizing patient selection, therapeutic positioning, and future biomarker-driven strategies.

MECHANISM OF ACTION

Tocilizumab is a humanized monoclonal IgG1 antibody that selectively binds to both membrane-bound and soluble interleukin-6 receptors (IL-6R), thereby inhibiting IL-6–mediated signaling [1]. IL-6 is a pleiotropic cytokine involved in B-cell differentiation, T-cell activation, acute-phase response, and hematopoiesis, and plays a pivotal role in chronic inflammation and autoimmunity [2]. IL-6 signaling occurs via classical signaling through membrane IL-6R and trans-signaling via soluble IL-6R, both of which activate downstream JAK-STAT and MAPK pathways [3]. By blocking IL-6R, tocilizumab suppresses inflammatory gene transcription, reduces acute-phase reactants such as C-reactive protein, and modulates adaptive immune responses. This dual inhibition of classical and trans-signaling underlies its therapeutic efficacy across multiple autoimmune and autoinflammatory disorders [1–3].



Note: Tocilizumab binds to both soluble and membrane-bound interleukin-6 receptors, thereby inhibiting IL-6–mediated classical and trans-signaling pathways and downstream JAK–STAT and MAPK/ERK activation. This results in suppression of inflammatory gene transcription, reduction of acute-phase reactants such as C-reactive protein, and modulation of immune cell responses.

Pharmacokinetics

Tocilizumab demonstrates nonlinear pharmacokinetics characteristic of monoclonal antibodies. It can be administered intravenously or subcutaneously, with subcutaneous bioavailability of approximately 80% [4]. Peak serum concentrations occur immediately after intravenous infusion, whereas subcutaneous administration reaches peak levels within 2–4 days [4]. Clearance is dose-dependent and occurs via both target-mediated elimination and nonspecific reticuloendothelial pathways. The terminal half-life ranges from 8 to 14 days depending on dose, route, and body weight [4,5]. Tocilizumab indirectly influences cytochrome P450 enzyme activity by suppressing IL-6, potentially increasing metabolism of drugs such as warfarin and statins [5]. No dose adjustment is required in renal impairment, while caution is recommended in hepatic dysfunction [4].

Tocilizumab in Connective Tissue Diseases

1. Systemic Lupus Erythematosus (SLE)

IL-6 contributes significantly to SLE pathogenesis by promoting B-cell hyperactivity, autoantibody production, and plasmablast survival [6]. An open-label phase I dose-escalation study demonstrated that tocilizumab reduced disease activity scores, anti-double-stranded DNA antibody levels, and circulating plasma cells in patients with mild to moderate SLE [7]. However, dose-dependent neutropenia and infections limited therapeutic escalation [7]. To date, no large phase III randomized controlled trials have demonstrated definitive clinical efficacy, and tocilizumab is not approved for SLE. Its use remains experimental and restricted to highly selected refractory cases [6,7].

2. Primary Sjögren's Syndrome

Elevated IL-6 levels correlate with systemic disease activity in primary Sjögren's syndrome [8]. Despite this, a multicenter double-blind randomized controlled trial failed to show significant improvement in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) with tocilizumab compared with placebo [9]. Secondary outcomes including fatigue and glandular function also showed no benefit [9]. Consequently, current evidence does not support routine use of tocilizumab in Sjögren's syndrome outside clinical trials [8,9].

3. Systemic Sclerosis

IL-6 is implicated in early inflammatory systemic sclerosis and the development of interstitial lung disease (ILD) [10]. The phase II faSScinate trial showed trends toward improvement in skin fibrosis and stabilization of lung function [11]. The phase III focuSSced trial demonstrated significant preservation of forced vital capacity, although improvement in skin fibrosis did not meet the primary endpoint [12]. Long-term extension studies confirmed sustained pulmonary benefit and acceptable safety [13]. Tocilizumab is now considered a disease-modifying therapy for selected patients with systemic sclerosis–associated ILD [10–13].

4. Idiopathic Inflammatory Myopathies

Idiopathic inflammatory myopathies exhibit increased IL-6 expression within inflamed muscle tissue [14]. A randomized phase II trial in refractory polymyositis and dermatomyositis failed to meet its primary efficacy endpoint despite acceptable safety [15]. Observational studies and systematic reviews, however, suggest that subsets of refractory patients may derive benefit, particularly those with inflammatory phenotypes [16]. At present, evidence is insufficient to recommend routine use of tocilizumab in myositis [15,16].

5. Giant Cell Arteritis

Giant cell arteritis is a prototypical IL-6–driven vasculitis. The landmark GiACTA trial demonstrated that tocilizumab significantly increased sustained glucocorticoid-free remission rates and markedly reduced cumulative glucocorticoid exposure compared with placebo [17]. Long-term real-world studies confirm durable remission and an acceptable safety profile [18]. Tocilizumab is now approved and recommended for relapsing or high-risk giant cell arteritis [17,18].

6. Takayasu Arteritis

Elevated IL-6 levels correlate with disease activity in Takayasu arteritis [19]. A randomized controlled trial showed a numerical reduction in relapse rates with tocilizumab, although the primary endpoint did not reach statistical significance [20]. Observational and multicenter cohort studies demonstrate clinical remission and steroid-sparing effects in refractory disease [21]. Tocilizumab is widely used off-label in Takayasu arteritis, particularly in relapsing cases [19–21].

7. Adult-Onset Still's Disease

Adult-onset Still's disease is an autoinflammatory disorder driven by IL-1 and IL-6 [22]. Tocilizumab has shown significant efficacy in controlling systemic symptoms, normalizing inflammatory markers, and reducing glucocorticoid dependence in randomized trials and real-world cohorts [23,24]. It is now considered a key biologic therapy for refractory or systemic disease phenotypes [22–24].

8. Castleman Disease

Multicentric Castleman disease is characterized by pathological IL-6 overproduction [25]. Tocilizumab demonstrated rapid and sustained improvement in constitutional symptoms, anemia, inflammatory markers, and lymphadenopathy in pivotal trials [26]. Long-term follow-up confirmed durable responses over five years with manageable safety [27]. Tocilizumab is an approved cornerstone therapy for multicentric Castleman disease [25–27].

Efficacy of Tocilizumab in Connective Tissue Disorders

Systemic Lupus Erythematosus (SLE)

Interleukin-6 (IL-6) plays a central role in SLE pathogenesis by promoting B-cell differentiation, autoantibody production, and plasmablast survival. Tocilizumab (TCZ), a humanized monoclonal antibody against the IL-6 receptor, has therefore been investigated as a targeted therapeutic strategy. The most substantial clinical evidence derives from an open-label phase I dose-escalation study involving patients with mild-to-moderate SLE, which demonstrated reductions in disease activity scores, anti-double-stranded DNA antibody levels, and circulating plasma cells following TCZ therapy [7]. These biological effects supported the mechanistic rationale for IL-6 blockade. However, dose-dependent neutropenia and infections were frequent, limiting dose escalation and raising safety concerns [7]. Subsequent clinical development of TCZ in SLE has been limited, with no large phase III randomized controlled trials (RCTs) demonstrating definitive clinical efficacy. While other IL-6 pathway inhibitors have been explored, results have been inconsistent, and IL-6 blockade has not achieved regulatory approval for SLE [1]. Current evidence suggests that TCZ may exert immunologic and serologic benefits but lacks robust data supporting its routine use for major organ involvement such as lupus nephritis or neuropsychiatric lupus. Consequently, TCZ remains an experimental or off-label option reserved for highly selected, refractory cases under close monitoring. Further well-designed RCTs are required to define optimal patient selection, dosing strategies, and long-term safety in SLE [1,7].

Primary Sjögren's Syndrome

Primary Sjögren's syndrome (pSS) is characterized by chronic inflammation and systemic immune activation, with elevated IL-6 levels correlating with disease severity. Despite strong biological plausibility, clinical trial data for TCZ in pSS have been largely disappointing. The most definitive evidence comes from a multicenter, randomized, double-blind, placebo-controlled trial evaluating

TCZ in patients with moderate to severe systemic disease activity. This study failed to demonstrate a significant improvement in the primary endpoint—reduction in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)—at 24 weeks compared with placebo [9]. Secondary outcomes, including patient-reported symptoms and glandular function, also showed no meaningful benefit [9]. Safety findings were consistent with the known profile of TCZ, without unexpected adverse events. These results indicate that IL-6 blockade does not translate into clinically meaningful systemic improvement in unselected pSS populations. Observational studies and smaller series have similarly failed to identify consistent responders or predictive biomarkers [28]. As such, current evidence does not support the routine use of TCZ in primary Sjögren's syndrome outside clinical trials. Future research may focus on molecularly defined subgroups or combination strategies, but TCZ is not recommended in standard pSS management at present [9,28].

Systemic Sclerosis

Systemic sclerosis (SSc) is a complex autoimmune disease characterized by immune activation, vasculopathy, and fibrosis. Elevated IL-6 levels are associated with early inflammatory disease and progressive interstitial lung disease (ILD). The phase II faSScinate trial demonstrated a trend toward improvement in skin fibrosis and stabilization of lung function with subcutaneous TCZ, providing the rationale for phase III evaluation [11]. The subsequent focuSSced trial, a randomized placebo-controlled phase III study, did not meet its primary endpoint of statistically significant improvement in modified Rodnan skin score; however, TCZ significantly preserved forced vital capacity (FVC), indicating a protective effect against progression of SSc-associated ILD [12]. Long-term open-label extension studies confirmed sustained preservation of lung function with acceptable safety profiles [13]. These findings have positioned TCZ as an important therapeutic option for early SSc with progressive ILD, and it has received regulatory approval for this indication in several regions. While the effect on skin fibrosis remains modest, the consistent pulmonary benefit underscores the importance of appropriate patient selection. TCZ is now considered a disease-modifying therapy for SSc-ILD in selected patients [11–13].

Idiopathic Inflammatory Myopathies

Idiopathic inflammatory myopathies (IIM) encompass heterogeneous disorders including polymyositis and dermatomyositis, with evidence of IL-6 overexpression in muscle tissue. A randomized, double-blind, placebo-controlled phase II trial evaluated TCZ in refractory polymyositis and dermatomyositis but failed to meet its primary and secondary efficacy endpoints at 24 weeks, despite an acceptable safety profile [15]. These results argue against broad efficacy of TCZ in unselected IIM populations. Nevertheless, multiple case series and observational studies have reported clinical improvement in subsets of patients, particularly those with refractory disease and prominent inflammatory features [16]. Improvements in muscle strength, creatine kinase levels, and inflammatory markers have been described in approximately half of treated patients in small cohorts [16]. The discrepancy between randomized and observational data suggests disease heterogeneity and the need for biomarker-guided patient selection. At present, TCZ is not recommended as standard therapy for IIM but may be considered experimentally in refractory cases under specialist supervision [15,16].

Giant Cell Arteritis

Giant cell arteritis (GCA) is a prototypical IL-6–driven vasculitis, and TCZ has transformed its management. The landmark GiACTA trial demonstrated that weekly or biweekly subcutaneous TCZ combined with a 26-week prednisone taper resulted in significantly higher rates of sustained glucocorticoid-free remission at 52 weeks compared with placebo plus prednisone taper [17]. TCZ also substantially reduced cumulative glucocorticoid exposure, addressing a major unmet need in GCA management. Long-term extension studies and real-world cohorts have confirmed durable efficacy and acceptable safety, with infections being the primary concern [18]. TCZ is now widely approved and recommended for relapsing or high-risk GCA patients, and in some settings, as part of

first-line therapy. Among all rheumatic diseases, the evidence supporting TCZ use is strongest in GCA [17,18].

Takayasu Arteritis

Takayasu arteritis (TAK) is a chronic large-vessel vasculitis with limited evidence-based treatment options. Elevated IL-6 levels correlate with disease activity, supporting IL-6 inhibition as a therapeutic strategy. A randomized controlled trial of TCZ in TAK showed a numerical reduction in relapse rates and longer time to relapse compared with placebo, although the primary endpoint did not reach statistical significance [20]. Multiple observational studies and meta-analyses have reported clinical remission, reduced inflammatory markers, and steroid-sparing effects in refractory TAK patients treated with TCZ [21]. Imaging outcomes suggest stabilization of vascular lesions in many cases, though progression can still occur. Despite limited RCT data, TCZ is widely used off-label for refractory TAK and is supported by expert consensus guidelines [20,21].

Adult-Onset Still's Disease

Adult-onset Still's disease (AOSD) is an autoinflammatory disorder characterized by cytokine dysregulation, particularly IL-1 and IL-6. TCZ has demonstrated efficacy in controlling systemic symptoms, reducing inflammatory markers, and enabling glucocorticoid tapering in multiple studies. Randomized trials and large observational cohorts have shown high response rates, particularly in systemic disease phenotypes [23]. Registry data confirm sustained remission and good drug retention, although macrophage activation syndrome remains a critical safety concern requiring careful monitoring [29]. TCZ is now considered an effective biologic option for steroid-dependent or refractory AOSD [23,29].

Castleman Disease

Multicentric Castleman disease (MCD) is a lymphoproliferative disorder driven by excessive IL-6 production. TCZ was one of the first targeted therapies shown to be effective in this condition. Early pivotal studies demonstrated rapid improvement in systemic symptoms, anemia, inflammatory markers, and lymphadenopathy [26]. Long-term follow-up studies extending up to five years confirmed sustained efficacy and manageable safety [27]. TCZ is approved for MCD in several countries and remains a cornerstone therapy, particularly in IL-6–driven disease. Among all indications discussed, the evidence base for TCZ is most robust and consistent in MCD [26,27].

Conclusion

Interleukin-6 (IL-6) is a pivotal cytokine driving inflammation, autoimmunity, and tissue damage across diverse connective tissue diseases. Tocilizumab, by targeting both soluble and membrane-bound IL-6 receptors, offers a rational and effective therapeutic strategy in selected conditions. The strongest evidence supports its use in giant cell arteritis and multicentric Castleman disease, where randomized controlled trials and long-term studies confirm durable remission and glucocorticoid-sparing benefits. In systemic sclerosis–associated interstitial lung disease, tocilizumab consistently preserves lung function, establishing its role as a disease-modifying therapy in carefully chosen patients. Moderate efficacy has been observed in adult-onset Still's disease and Takayasu arteritis, while results in systemic lupus erythematosus, primary Sjögren's syndrome, and idiopathic inflammatory myopathies remain inconclusive or negative, limiting its use to refractory or experimental settings.

Overall, tocilizumab exemplifies the promise and limitations of cytokine-targeted therapy in heterogeneous autoimmune disorders. Its variable efficacy underscores the need for precise patient selection, biomarker-guided approaches, and further well-designed randomized trials to define optimal indications, dosing strategies, and long-term safety. As our understanding of IL-6 biology deepens, tocilizumab is likely to remain a cornerstone therapy in specific connective tissue diseases, while serving as a model for future targeted interventions in immune-mediated conditions.

Table 1. Comparative efficacy of tocilizumab across immune-mediated diseases
Abbreviations: RCT – randomized controlled trial; mRSS – modified Rodnan skin score; FVC – forced vital capacity; ESSDAI – EULAR Sjögren's Syndrome Disease Activity Index; CRP – C-reactive protein; NS – not significant.

Disease	Study (Author, Year)	Study design	Sample size	Primary efficacy endpoint	Key efficacy result	Strength of evidence
Systemic lupus erythematosus	Illei et al., 2010	Open-label phase I	16	Disease activity, serology	↓ SLEDAI, ↓ anti-dsDNA, ↓ plasmablasts; dose-limiting neutropenia	Low
Primary Sjögren's syndrome	Felten et al., 2021	Double-blind RCT	110	ESSDAI response at 24 weeks	No significant difference vs placebo	High (negative)
Systemic sclerosis	Khanna et al., 2016 (faSScinate)	Phase II RCT	87	mRSS; FVC	Trend toward ↓ mRSS; stabilization of FVC	Moderate
	Khanna et al., 2020 (focuSSced)	Phase III RCT	210	Change in mRSS; FVC	Primary endpoint NS; significant preservation of FVC	Moderate
	Roofeh et al., 2021	Open-label extension / post-hoc	210	Change in FVC	Sustained attenuation of ILD progression	Moderate
Idiopathic inflammatory myopathies	Oddis et al., 2022	Phase II RCT	36	Total improvement score	Primary endpoint not met	Moderate (negative)
	Li et al., 2021	Systematic review	7 studies	Clinical response	≈50–60% response in refractory disease (observational)	Low–moderate
Giant cell arteritis	Stone et al., 2017 (GiACTA)	Phase III RCT	251	Sustained remission at 52 weeks	Significantly higher remission; marked steroid-sparing	High
	Calderón-Goercke et al., 2024	Real-world cohort	134	Relapse-free survival	Durable remission with acceptable long-term safety	High
Takayasu arteritis	Nakaoka et al., 2018	Double-blind RCT	36	Time to relapse	Numerical benefit; primary endpoint NS	Low–moderate
	Mekinian et al., 2020	Multicenter retrospective cohort	46	Clinical remission; steroid-sparing	≈70% remission; reduced glucocorticoid exposure	Moderate
Adult-onset Still's disease	Kaneko et al., 2018	Phase III RCT	27	Systemic response	Improved systemic symptoms and inflammation	Moderate
	Sota et al., 2022	Multicenter cohort	57	Clinical remission	High remission and steroid-sparing effect	Moderate

Castleman disease	Nishimoto et al., 2005	Open-label pivotal study	28	Symptom and CRP normalization	Rapid clinical and biochemical improvement	High
	Nishimoto et al., 2007	Long-term follow-up	–	Durability of response	Sustained efficacy up to 5 years	High

REFERENCES

1. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, et al. Tocilizumab inhibits signal transduction mediated by both soluble and membrane-bound interleukin-6 receptors. *Clin Rev Allergy Immunol.* 2012;42(2):164–173. doi:10.1007/s12016-011-8283-z.
2. Kishimoto T. Interleukin-6: from basic science to medicine—40 years in immunology. *Blood.* 2005;106(7):2243–2249. doi:10.1182/blood-2005-02-0842.
3. Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. *Nat Rev Rheumatol.* 2017;13(7):399–409. doi:10.1038/nrrheum.2017.83.
4. European Medicines Agency (EMA). RoActemra® (tocilizumab): Summary of Product Characteristics. Amsterdam: EMA; 2023.
5. Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease–drug–drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. *Clin Pharmacol Ther.* 2011;89(5):735–740. doi:10.1038/clpt.2011.38.
6. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. *Arthritis Rheum.* 2004;50(9):2751–2760. doi:10.1002/art.20453.
7. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. *Arthritis Rheum.* 2010;62(2):542–552. doi:10.1002/art.27221.
8. Mavragani CP, Fragoulis GE, Moutsopoulos HM. Cytokines in Sjögren's syndrome: IL-6 and beyond. *J Autoimmun.* 2010;35(3):199–205. doi:10.1016/j.jaut.2010.06.015.
9. Felten R, Ravaud P, Mariette X, Berenbaum F, Gottenberg JE, Salliot C, et al. Interleukin-6 receptor inhibition in primary Sjögren's syndrome: a multicentre double-blind randomised placebo-controlled trial. *Ann Rheum Dis.* 2021;80(3):329–338. doi:10.1136/annrheumdis-2020-218467.
10. Denton CP, Khanna D. Systemic sclerosis. *Lancet.* 2017;390(10103):1685–1699. doi:10.1016/S0140-6736(17)30933-9.
11. Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. *Lancet.* 2016;387(10038):2630–2640. doi:10.1016/S0140-6736(16)00232-4.
12. Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, et al.; focuSSced investigators. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. *N Engl J Med.* 2020;382(23):2238–2249. doi:10.1056/NEJMoa1919845.
13. Roofeh D, Lin CJF, Goldin J, Kim GHJ, Furst DE, Denton CP, et al. Tocilizumab prevents progression of early systemic sclerosis–associated interstitial lung disease. *Arthritis Rheumatol.* 2021;73(7):1301–1310. doi:10.1002/art.41668.
14. De Bleecker JL, Meire VI, Declercq W, Van Aken EH. Cytokine expression in idiopathic inflammatory myopathies. *Cytokine.* 2002;18(5):235–241. doi:10.1006/cyto.2002.0896.
15. Oddis CV, Reed AM, Aggarwal R, Koontz DC, Fertig N, Catlett J, et al. Tocilizumab in patients with refractory polymyositis and dermatomyositis: a randomized, double-blind, placebo-controlled phase 2B study. *Arthritis Rheumatol.* 2022;74(7):1160–1170. doi:10.1002/art.42045.

16. Li S, Sun Y, Shao X, Zhang L, Wang Q. The efficacy and safety of tocilizumab in idiopathic inflammatory myopathies: a systematic review. *Front Pharmacol.* 2021;12:786485. doi:10.3389/fphar.2021.786485.
17. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. *N Engl J Med.* 2017;377(4):317–328. doi:10.1056/NEJMoa1613849.
18. Calderón-Goercke M, Loricera J, Aldasoro V, Villa I, Humbría A, González-Gay MA. Long-term tocilizumab therapy in giant cell arteritis: clinical outcomes and safety. *Rheumatology (Oxford).* 2024;63(1):123–132. doi:10.1093/rheumatology/kead410.
19. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. *Ann Intern Med.* 1994;120(11):919–929. doi:10.7326/0003-4819-120-11-199406010-00004.
20. Nakaoka Y, Isobe M, Takeuchi T, Tanaka Y, Yokota S, Tanaka F, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomized, double-blind, placebo-controlled trial. *Ann Rheum Dis.* 2018;77(3):348–354. doi:10.1136/annrheumdis-2017-211878.
21. Mekinian A, Resche-Rigon M, Comarmond C, Mirault T, Kahn JE, Lambert M, et al. Efficacy of tocilizumab in Takayasu arteritis: multicenter retrospective study of 46 patients. *Autoimmun Rev.* 2020;19(2):102517. doi:10.1016/j.autrev.2019.102517.
22. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still's disease. *Autoimmun Rev.* 2014;13(7):708–722. doi:10.1016/j.autrev.2014.01.058.
23. Kaneko Y, Kameda H, Ikeda K, Yamaoka K, Takeuchi T. Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid therapy: a randomized, double-blind, placebo-controlled phase III trial. *Ann Rheum Dis.* 2018;77(12):1720–1729. doi:10.1136/annrheumdis-2018-213820.
24. Sota J, Vitale A, Rigante D, Lopalco G, Franceschini R, Emmi G, et al. Efficacy and safety of tocilizumab in adult-onset Still's disease: a multicenter retrospective study. *Clin Exp Rheumatol.* 2022;40(6):1123–1131.
25. Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease. *Blood.* 2017;129(12):1646–1657. doi:10.1182/blood-2016-10-746933.
26. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease. *Blood.* 2005;106(8):2627–2632. doi:10.1182/blood-2005-03-1108.
27. Nishimoto N, Honda O, Sumikawa H, Johkoh T, Aozasa K, Kanakura Y. Long-term (5-year) sustained efficacy of tocilizumab for multicentric Castleman's disease. *Blood.* 2007;110(11):646.
28. Mariette X, Criswell LA. Primary Sjögren's syndrome. N Engl J Med. 2018;378(10):931–939. doi:10.1056/NEJMcp1702514.
29. Sota J, Vitale A, Rigante D, Lopalco G, Franceschini R, Emmi G, et al. Efficacy and safety of tocilizumab in adult-onset Still's disease: a multicenter retrospective study. Clin Exp Rheumatol. 2022;40(6):1123–1131.